cr.appliance
Concepts & Solutions in Drug Development

ACCP
American College of Clinical Pharmacology

member of BioLAGO life science network

DMdg DRUG METABOLISM discussion group

DDI 2011 – 2nd International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

May 01st to 03rd, 2011
Marbach Castle, Germany

Final Announcement

SCOPE AND AIM

In May/June 2010 the first International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions was held based on the initiative of a group of international scientists and experts from academia and pharmaceutical industry.

The event was triggered by the notion that the area of drug-drug interactions (DDIs) is getting increasingly important and complex in view of continuously emerging new therapies, complex treatment algorithms for many widespread disease states and ageing populations in the industrialized countries. These factors converge into a frequently employed poly-pharmacotherapy with increasing risks for clinically significant DDIs. These developments represent substantial challenges for the pharmaceutical industry and regulatory bodies in the development and approval of new medicines, which need to be carefully and comprehensively considered by all stakeholders and decision makers involved in the drug development process.

Failures in the early recognition, mechanistic elucidation (understanding) and proper management of DDIs, in turn, have resulted in significant health burden to patients, serious public safety concerns and drug withdrawals from the market in the past.

Today, however, the principle challenges in the investigation and prediction of adverse DDIs can be generally addressed in a more targeted and evidence-based fashion, because considerable progress has been made in the understanding of the underlying mechanisms of DDIs and the subsequent development of methodologies for the investigation of DDI susceptibility, and the extrapolation of outcomes of particular DDIs to other drug combinations.

In Europe, the scientific progress in the field over the last years is now reflected in the current draft version of the revised Note for Guidance Document on the Investigation of Drug Interactions (EMA / CHMP / EWP / 125211 / 2010) that was issued by the European Medicines Agency on April 22, 2010. Hence, a new regulatory framework is available to serve as a platform and regulatory benchmark for the discussion of essential requirements, methodologies and best practices in the field.

The 2010 Workshop combined a regulatory update on the investigation of DDIs from the European Rapporteur perspective (MPA, Sweden) along with a scientific update focusing on the investigation of metabolism- and transporter-based DDIs. Around 70 experts from pharmaceutical industry, contract research organisations and drug regulatory agencies from 10 European countries and the United States participated in the 1st International DDI Workshop at Marbach Castle. Based on the detailed feedback received from the expert audience on additional areas of interest requiring future consideration, the structure and content of the present Workshop was designed.

The topics of the 2nd Marbach Castle meeting will be covered by international scientists and experts from academia, pharmaceutical companies, contract research organizations, consultancies and regulators. The program will provide a unique opportunity for scientific exchange and networking across company and organizational borders, and an opportunity to learn about the current state-of-the-art in the investigation of DDIs.

The organisers:

Hartmut Derendorf PhD, FCP
Robert Hermann MD, FCP
Amin Rostami-Hodjegan PharmD PhD, FCP
Oliver von Richter PhD, FCP

BENEFITS IN ATTENDING

- **Focus** on regulatory aspects and scientific challenges of DDIs related to large molecules (biologics)
- **Optimize** your knowledge about in vitro approaches in the assessment of the enzyme-suppressing effects of large molecule drugs (biologics)
- **Take time** to reflect about the clinical and strategic impact of adverse drug-drug interactions
- **Learn more** about handling complex DDIs involving various mechanisms
- **Hear** the update on current US-perspective on the investigation of DDIs
- **Learn and discuss** the new regulatory requirements for in vitro and in vivo drug-drug interaction (DDI) studies in Europe as detailed in the new EMA Draft Guideline on the investigation of drug interactions
- **Discover** the commonalities and differences between regulatory US- and EU-requirements
- **Gain** insights and a thorough understanding of complex and clinically important DDIs in various therapeutic areas of particular interest such as immunosuppressant and anti-infective therapy, oncology, and cardiovascular disease
- **Learn** about widely neglected DDIs in oncology
- **Understand** the mechanisms, investigational approaches and clinical significance of DDIs affecting intestinal absorption
- **Update** yourself on the role of pharmacodynamic DDIs of cardiovascular drugs with a particular emphasis on QT/QTc prolongation
- **Inform** yourself about transporter-related DDIs of hepatic uptake and elimination
- **Meet, discuss and network** with scientific and regulatory experts from Pharma- and CRO-industries, international regulatory bodies, and academia

WORKSHOP PROGRAMME

May 1st, 2011

Sunday

Afternoon	Individual Arrival & Check-in at Marbach Castle
05:00 p.m.	Registration & Coffee
06:00 p.m.	Come Together Activities
08:00 p.m.	Come Together Dinner

May 2nd, 2011

Monday

08:00 – 09:00 a.m.	Registration & Coffee
09:00 – 09:10 a.m.	Welcome & Introduction to the Workshop *Robert Hermann, MD, FCP; cr.appliance, Germany*
09:10 – 09:40 a.m.	The Burden of Drug-Drug Interactions – An Update of the Clinical Perspective *Robert Hermann, MD, FCP; cr.appliance, Germany*
09:40 – 9:50 a.m.	Discussion
	Session I: **Large Molecule Interactions**
09:50 – 10:20 a.m.	Large Molecule – Drug Interactions: A Change in Perspective *Oliver von Richter, PhD, FCP; MerckSerono, Germany*
10:20 – 10:30 a.m.	Discussion
10:30 – 11:00 a.m.	Coffee Break
	Session I: **Large Molecule Interactions (ctd)**
11:00 – 11:45 a.m.	*In vitro* Approaches to Assessing the Enzyme-Suppressing Effects of Large Molecule Drugs *Andrew Parkinson, PhD; XenoTech LLC, Lenaxa, Kansas, USA*
11:45 – 11:55 a.m.	Discussion
11:55 – 12:40 a.m.	Clinical Drug Interaction Studies of Large Molecule Drugs: Necessity, Options and Challenges *Bernd Liedert, PhD, MerckSerono, Germany*
12:40 – 12:50 p.m.	Discussion
12:50 – 02:30 p.m.	Lunch

May 2nd, 2011	Session II: Regulatory Sciences
02:30 – 03:15 p.m.	Update and Debate on the FDA's Current Thinking on the Investigation of Drug-Drug Interactions *Speakers: Hartmut Derendorf & Amin Rostami-Hodjegan*
03:15 – 03:30 p.m.	Discussion
03:30 – 04:30 p.m.	Commentaries & Joint Discussions of the Current European Draft Note for Guidance on the Investigation of Drug Interactions from Various Perspectives *Speakers/Facilitators: Robert Hermann, Bernd Liedert, Oliver von Richter, Andrew Parkinson, Amin Rostami-Hodjegan*
04:30 – 05:00 p.m.	Coffee Break
	Session III: Role of M&S in Regulatory Aspects of DDIs
05:00 – 05:45 p.m.	Increasing Role of M&S in Assessing Complex DDIs: Special Populations (Elderly, Renal- and Hepatic Impairment) and DDI Caused by Large Molecules *Amin Rostami-Hodjegan, PharmD, PhD, FCP; Faculty of Medical and Human Sciences University of Manchester, UK.*
05:45 – 06:00 p.m.	Discussion
07:00 p.m.	Dinner
08:30 p.m.	Concert „The Certain Something"

May 3rd, 2011

Tuesday

07:00 – 08:30 a.m.	Breakfast
	Session IV: **PK and PD DDIs in Special Therapeutic Indications**
08:30 – 09:15 a.m.	Drug-Drug Interactions in Oncology – A Widely Neglected Problem? *Alex Sparreboom, PhD, St. Jude Children's Research Hospital, Memphis, TN, USA*
09:15 – 09:25 a.m.	Discussion
09:25 – 10:10 a.m.	Drug-Drug Interactions in the Development of Anticancer Drugs: Strategies for Risk Assessment, Management and Clinical Evaluation *Karthik Venkatakrishnan, PhD; Millennium, Cambridge, USA*
10:10 – 10:20 a.m.	Discussion
10:20 – 10:45 a.m.	Coffee Break
10:45 – 11:30 a.m.	Immunosuppressants: Drug-Drug, Drug-Metabolite, Drug-Disease Interactions as Well as All Possible Combinations Thereof *Uwe Christians, MD, PhD; University of Colorado, Denver, USA*
11:30 – 11:40 a.m.	Discussion
11:40 – 12:25 p.m.	Benefits and Risks of Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions in Anti-Infective Therapy *Hartmut Derendorf, PhD, FCP; College of Pharmacy, University of Florida, USA*
12:25 – 12:35 p.m.	Discussion
12:35 – 02:00 p.m.	Lunch

Session IV
PK and PD DDIs in Special Therapeutic Indications (ctd)

2:00 – 2:45 p.m.	PK and PD-Interactions – Including Drug-Drug Interactions Affecting the QT/QTc interval of the ECG – with Cardiovascular Medicinal Products. *Wilhelm Haverkamp, MD, PhD; Department of Cardiology, Charité Berlin, Germany*
2:45 – 02:55 p.m.	Discussion

Session V:
Non-Metabolic DDIs in Drug Absorption and Disposition

2:55 – 03:40 p.m.	Drug-Drug Interactions Affecting Intestinal Absorption: Mechanisms, Investigational Approaches and Clinical Significance. *Thomas Gramatté, MD, PhD; Drug Development Consulting, Munich, Germany*
03:40 – 03:50 p.m.	Discussion
03:50– 04:20 p.m.	Food and Formulation Interactions Affecting Drug Absorption: Mechanisms and Predictability using M&S. *Michael Bolger, PhD, Simulations Plus, Inc., Lancaster, USA*
04:20 – 04:30 p.m.	Discussion
04:30 – 05:00 p.m.	Transporter-Based Drug Interactions of Hepatic Uptake and Elimination: How to Assess Insights Into Effect-Sizes of Hepatic Transporter-Function Impairment and Putting this into Clinical Perspective. *Christian de Mey, MD, PhD; ACPS – Applied Clinical Pharmacology Services, Mainz-Kastel, Germany*
05:00 – 05:10 p.m.	Discussion
05:10 – 05:15 p.m.	Concluding Remarks *Robert Hermann, MD, FCP; cr.appliance, Germany*
05:15 p.m.	Coffee Break; End of Meeting & Individual Departure

WHO SHOULD ATTEND?

This international Workshop on drug-drug interactions is designed to meet the requirements and expectations of professionals from the pharmaceutical industry, contract research organisations, regulatory agencies and academia.

Department heads, project managers, scientists and consultants in R&D, in regulatory affairs, pharmacokinetics, clinical pharmacology, exploratory medicine, clinical development, biostatistics, business development, medical communications and so forth should attend. All delegates are invited to contribute actively to the scientific discussions.

LANGUAGE

English will be the language of the Workshop. No simultaneous translation will be provided.

VENUE & LOCATION

The Workshop will take place at the Marbach Castle Conference Centre (see the following web site: www.schlossmarbach.de), located close to the Swiss border on the beautiful surrounding of the Western shore of Lake Constance in close proximity to the historic town of Stein am Rhein. The old town centre of Stein am Rhein is characterised by striking medival buildings such as the City Church, the former Monastery of St. Georgen, burghers' houses, gates and towers, as well as buildings dating from the early modern age, including the Town Hall and the Arsenal.

Marbach Castle is within easy reach of the major cities in the area (Zurich, Basel, Stuttgart, Constance, Freiburg). The distance from the Zurich International Airport Airport is about 60 kilometres. Taxi from and to the Airport is approx. 80 Euros. Airport taxi shuttles for Workshop attendees can be organised upon request. If driving, please find detailed itinerary descriptions posted under the Contact/ Travelling menue of the Marbach Castle web site.

REGISTRATION INFORMATION

Date	Workshop May, 1st to 3rd, 2011
Venue	Marbach Castle D-78337 Öhningen +49 (0)7735 – 8130 info@schlossmarbach.de
Times	May 1st, 2011 Afternoon: Individual arrival, come together, Come together activity, come together dinner May 2nd, 2011 Start 09:00 a.m. – Finish 06:20 p.m. May 3rd, 2011 Start 09:00 a.m. – Finish 05:15 p.m.
Registration & Coffee	May 1st, 2011 – 04:00 p.m.

MAP



cr.appliance
Concepts & Solutions in Drug Development

Registration Form

Please print your details

Title	First name
Family name	
Position	
Department	
Company	
Address	
City	Post Code
Country	
Phone	Fax
E-mail	
Date	Signature

You may register at:

cr.appliance
Rossittenstraße 15
D-78315 Radolfzell
Fax: +49 (0)7732-820 953
Internet: www.cr-appliance.com
E-mail: karen.grave-hermann@cr-appliance.com

For further information please contact Karen Grave-Hermann
Phone: +49 (0)7732-820 951

Cancellation Policy

- Over 30 days prior to the Seminar: Cancellation fee of 75,00 €.
- 14 – 29 days prior to the Seminar: 50 % of the fee.
- Fewer than 14 days or if no notification received: Registrant liable to pay FULL seminar fee.

NB: Cancellation must be addressed in writing to karen.grave-hermann@cr-appliance.com

In the event circumstances beyond control, cr.appliance reserves the right to alter the programme, the speakers, the date or the venue.

cr.appliance
Concepts & Solutions in Drug Development

Workshop Fee (incl. Lunch, Dinner & Coffee Breaks, incl. 19 % VAT)

Please tick

Participation from May 1st to 3rd, 2011	1.750,00 €	☐
Early bird fee, (i.e. registration and payment of workshop fee until end of January 2011) or members of ACCP, DMDG or BioLago (Full participation from May 1st to 3rd, 2011)	1.650,00 €	☐
Participation on May 2nd to 3rd, 2011 only	1.650,00 €	☐
Participation on May 2nd to 3rd, 2011 only, in combination with early bird fee (conditions see above) or membership of ACCP, DMDG or BioLago	1.550,00 €	☐

Accommodation (incl. Breakfast and 19 % VAT)

A limited number of bedrooms are available at Marbach Castle (further Hotel capacities in close proximity available upon request):		1 night	2 nights
Category A:	single room (160,00 € per night)	☐	☐ (= 320 €)
	double room (200,00 € per night)	☐	☐ (= 400 €)
Category B:	single room (111,00 € per night)	☐	☐ (= 222 €)
	double room (151,00 € per night)	☐	☐ (= 302 €)
No Hotel accommodation required:			☐

Application to Register

To ensure the personal workshop character of the event and provide maximum knowledge transfer benefits for the attendees, the overall number of participants is limited. Workshop participation will be assigned in the sequence of receipt of registration applications. Full confirmation of registration will occur by receipt of the Workshop fees.

Discounted Rates

An “early bird” discount of 100 € will be granted for all binding bookings with actual payment of the workshop fee by end of January 2011. Discounted workshop fees for members of DMDG, ACCP and BioLago will be granted as indicated in the respective table based on proven evidence of current membership (e.g. membership card). Further discounted rates may be granted for a limited number of participants on individual application for students, personnel from non-profit organizations and registered charities.